Safety and Tolerability of Varenicline Tartrate (Champix ® /Chantix ® ) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The prevalence of smoking in HIV-infected subjects is high. As a smoking cessation aid, varenicline (Champix(®), Pfizer, Saint-Laurent, QC, Canada or Chantix(®), Pfizer, Mission, KS) has not been previously evaluated in HIV-infected smokers. In this multicenter pilot open label study, varenicline 1.0 mg was used twice daily for 12 weeks with dose titration in the first week. Adverse events (AEs) during the treatment period were recorded. Changes from baseline in laboratory tests, vital signs, daily cigarette consumption, nicotine dependence, and withdrawal were measured through week 24. Self-reported abstinence was validated by serum cotinine at week 12. We enrolled 36 subjects with a mean of 29 pack-years of smoking and a minimum of 4 cigarettes per day. All but 1 were male, 33 (92%) were white. The most frequently reported AEs were nausea (33%), abnormal dreams (31%), affect lability (19%), and insomnia (19%). Six (17%) subjects discontinued varenicline due to AEs. No grade 3/4 laboratory abnormalities or serious AEs occurred during the study. There was no significant change in HIV viral load. CD4 counts increased by 69 cells/mm3 (p = 0.001) at week 24. Serum cotinine-verified 4-week continuous abstinence rate through weeks 9-12 was 42% (95% confidence interval [CI]: 26-58%). AEs and abstinence rates were comparable to those in published randomized controlled trials conducted in generally healthy HIV-negative smokers. Varenicline was safe and appears effective among HIV-infected smokers in this exploratory study, although AEs were common. The most common AE was nausea, with no adverse effect on HIV treatment outcome. Close monitoring of liver enzymes and blood pressure is recommended for HIV-positive smokers taking varenicline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221 · cited 4×
“CD4 count, cells/mm(3), n = 36 601 (291) - 2 (22) 20 (23) 69 (20) Log10 viral load if detectable, n = 6 3.”
BackgroundInfluentialSigns and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598 · cited 2×
“CD4 count, cells/mm(3), n = 36 601 (291) - 2 (22) 20 (23) 69 (20) Log10 viral load if detectable, n = 6 3.”
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521 · cited 2×
“Subjects who had any one of the following seven conditions were excluded: (1) pregnant or nursing women; (2) allergy to varenicline; (3) cancer or transplant; (4) epilepsy, on antiepileptic drugs, on antidepressants, or antipsychotic drugs; (5) significant cardiovascular disease, uncontrolled hypertension, or cataract…”
BackgroundTobacco withdrawal in self-quitters
Hughes, J. R. (1992) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.60.5.689 · Cited by 412
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Cited by
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Suissa, K., Larivière, J., Eisenberg, M. J., Eberg, M., Gore, G. C., Grad, R., Joseph, L., Reynier, P. M., & Filion, K. B. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002458 · Cited by 109
Metadata
- Authors
- Cui, Q., Robinson, L., Elston, D., Smaill, F., Cohen, J., Quan, C., McFarland, N., Thabane, L., McIvor, A., Zeidler, J., & Smieja, M.
- Venue
- AIDS Patient Care and STDs
- Publisher
- SAGE Publications
- Published
- 2012-01
- Volume
- 26
- Issue
- 1
- Pages
- 12-19
- ISSN
- 1087-2914 (ISSN-L)
- 1557-7449
- OpenAlex
- W2073429128
- Cited by
- 69
- References
- 10
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Tolerability of Varenicline Tartrate (Champix ® /Chantix ® ) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study. https://app.cochat.ai/papers/10.1089/apc.2011.0199
- The paper
- Cui, Q., Robinson, L., Elston, D., Smaill, F., Cohen, J., Quan, C., McFarland, N., Thabane, L., McIvor, A., Zeidler, J., & Smieja, M. (2012). Safety and Tolerability of Varenicline Tartrate (Champix ® /Chantix ® ) for Smoking Cessation in HIV-Infected Subjects: A Pilot Open-Label Study. AIDS Patient Care and STDs. https://doi.org/10.1089/apc.2011.0199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.